Remogliflozin etabonate
（重定向自Remogliflozin）
Remogliflozin etabonate (INN/USAN) is a proposed drug of the gliflozin class for the treatment of type 2 diabetes, investigated by GlaxoSmithKline. Remogliflozin is now being developed by BHV Pharma with Islet Sciences.